TY - JOUR
T1 - The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors
AU - Zhang, Zheng
AU - Lanz, Rainer B.
AU - Xiao, Lijuan
AU - Wang, Lei
AU - Hartig, Sean M.
AU - Ittmann, Michael M.
AU - Feng, Qin
AU - He, Bin
N1 - Funding Information:
This work has been supported by NIH K01DK081446 (B.H.), American Cancer Society RSG-13-061-01-TBE (B.H.), Department of Defense BC122115 (Q. F.), NIH R21AI122418 (Q. F.), CNIHR (Q. F.), NIH K01DK096093 (S.M.H.), NIH R03DK105006 (S.M.H.), American Heart Association Beginning Grant-in-Aid 15BGIA25850025 (S.M.H.), and Dan L. Duncan Cancer (P30 CA125123) supporting Human Tissue Acquisition and Pathology (M.I.).
PY - 2016
Y1 - 2016
N2 - The TMPRSS2-ERG fusion occurs in approximately 50% of prostate cancer (PCa), resulting in expression of the oncogenic ERG in the prostate. Because ERG is a transcriptional activator, we hypothesized that ERG-regulated genes contribute to PCa development. Since microRNA (miRNA) has crucial functions in cancer, we searched for miRNAs regulated by ERG in PCas. We mined published datasets based on the MSKCC Prostate Oncogene Project, in which a comprehensive analysis defined the miRNA transcriptomes in 113 PCas. We retrieved the miRNA expression datasets, and identified miRNAs differentially expressed between ERG-positive and ERG-negative samples. Out of 369 miRNAs, miR-200a, -200b, -429 and -205 are the only miRNAs significantly increased in ERG-positive tumors. Strikingly, miR-200a, -200b and -429 are transcribed as a single polycistronic transcript, suggesting they are regulated at the transcriptional level. With ChIP-qPCR and in vitro binding assay, we identified two functional ETS motifs in the miR-200b/a/429 gene promoter. Knockdown of ERG in PCa cells reduced expression of these three miRNAs. In agreement with the well-established tumor suppressor function, overexpression of the miR-200b/a/429 gene inhibited PCa cell growth and invasion. In summary, our study reveals that miR- 200b/a/429 is an ERG target gene, which implicates an important role in TMPRSS2/ ERG-dependent PCa development. Although induction of the tumor suppressive miR- 200b subfamily by oncogenic ERG appears to be counterintuitive, it is consistent with the observation that the vast majority of primary prostate cancers are slow-growing and indolent.
AB - The TMPRSS2-ERG fusion occurs in approximately 50% of prostate cancer (PCa), resulting in expression of the oncogenic ERG in the prostate. Because ERG is a transcriptional activator, we hypothesized that ERG-regulated genes contribute to PCa development. Since microRNA (miRNA) has crucial functions in cancer, we searched for miRNAs regulated by ERG in PCas. We mined published datasets based on the MSKCC Prostate Oncogene Project, in which a comprehensive analysis defined the miRNA transcriptomes in 113 PCas. We retrieved the miRNA expression datasets, and identified miRNAs differentially expressed between ERG-positive and ERG-negative samples. Out of 369 miRNAs, miR-200a, -200b, -429 and -205 are the only miRNAs significantly increased in ERG-positive tumors. Strikingly, miR-200a, -200b and -429 are transcribed as a single polycistronic transcript, suggesting they are regulated at the transcriptional level. With ChIP-qPCR and in vitro binding assay, we identified two functional ETS motifs in the miR-200b/a/429 gene promoter. Knockdown of ERG in PCa cells reduced expression of these three miRNAs. In agreement with the well-established tumor suppressor function, overexpression of the miR-200b/a/429 gene inhibited PCa cell growth and invasion. In summary, our study reveals that miR- 200b/a/429 is an ERG target gene, which implicates an important role in TMPRSS2/ ERG-dependent PCa development. Although induction of the tumor suppressive miR- 200b subfamily by oncogenic ERG appears to be counterintuitive, it is consistent with the observation that the vast majority of primary prostate cancers are slow-growing and indolent.
KW - ERG
KW - MiR-200
KW - MiR-205
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84978079881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978079881&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.9366
DO - 10.18632/oncotarget.9366
M3 - Article
C2 - 27191272
AN - SCOPUS:84978079881
SN - 1949-2553
VL - 7
SP - 37993
EP - 38003
JO - Oncotarget
JF - Oncotarget
IS - 25
ER -